A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin
详细信息 查看全文
- 作者：Lai Wei ; Mingxiang Zhang ; Min Xu ; Wan-Long Chuang ; Wei Lu ; Wen Xie ; Zhansheng Jia ; Guozhong Gong ; Yueqi Li ; Si Hyun Bae ; Yong-Feng Yang ; Qing Xie ; Shumei Lin ; Xinyue Chen ; Junqi Niu ; Jidong Jia ; Tushar Garimella ; Anne Torbeyns ; Fiona McPhee ; Michelle Treitel ; Philip D. Yin and Ling Mo
- 刊名：Journal of Gastroenterology and Hepatology
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：31
- 期：11
- 页码：1860-1867
- 全文大小：564K
- ISSN：1440-1746
文摘
Daclatasvir plus asunaprevir has demonstrated efficacy and safety in patients with chronic hepatitis C virus genotype 1b infection. This study focused on evaluating daclatasvir plus asunaprevir in interferon (±ribavirin)-ineligible or -intolerant Asian patients with genotype 1b infection from mainland China, Korea, and Taiwan.